Serum Golgi Protein 73 is Not a Suitable Diagnostic Marker for Hepatocellular Carcinoma

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Feb 4

PMID 28157705

Citations 22

Authors

Tianhui Liu

Mingjie Yao

Shuhong Liu

Lu Wang

Leijie Wang

Jinlin Hou

Xiong Ma

Jidong Jia

Jingmin Zhao

Hui Zhuang

Fengmin Lu

Affiliations

Soon will be listed here.

Abstract

Golgi protein 73 (GP73) has been suggested as a serum marker for the diagnosis of hepatocellular carcinoma (HCC). However, this has been challenged in recent years. In the present study, we found that the serum GP73 increased in HCC patients with cirrhosis but not in those without cirrhosis. The receiver operating characteristic curve (ROC) analysis demonstrated that serum GP73 had poor performance for differentiating HCC patients from cirrhosis patients. In addition, the immunohistochemistry revealed that aberrant expression of GP73 was primarily observed in cirrhotic and tumor liver tissues from both cirrhosis and HCC patients, but rarely in non-cirrhotic liver tissues from HCC patients without cirrhosis. Moreover, serum Alpha-fetoprotein in HCC patients with cirrhosis decreased sharply after resection of tumor tissue, while the serum GP73 remained stable. These data indicated that the background of cirrhosis was related to the elevation of serum GP73 in HCC patients. In conclusion, serum GP73 is not a suitable diagnostic marker for HCC.

Citing Articles

Diagnostic and Prognostic Value of Serum Golgi Protein 73 in Patients With Hepatitis B Virus-Associated Acute-on-Chronic Liver Failure.

Xu Z, Xu T, Ye Q, Li Y, Yang T, Zhang X Immun Inflamm Dis. 2025; 13(2):e70120.

PMID: 39912564 PMC: 11800233. DOI: 10.1002/iid3.70120.

Whether the Golgi protein 73 could be a diagnostic serological marker in hepatocellular carcinoma: a meta analysis.

Zhang X, Wu L, Li X, Luo X, Liu S, Zhang L BMC Gastroenterol. 2023; 23(1):85.

PMID: 36964524 PMC: 10039610. DOI: 10.1186/s12876-023-02685-8.

Relationship between the Level of Serum Golgi Protein 73 and the Risk of Short-term Death in Patients with ALD-ACLF.

Tong J, Yao M, Mu X, Wang L, Wen X, Zhai X J Clin Transl Hepatol. 2022; 10(3):449-457.

PMID: 35836755 PMC: 9240251. DOI: 10.14218/JCTH.2020.00133.

Diagnostic Value of Serum Golgi Protein 73 for Liver Inflammation in Patients with Autoimmune Hepatitis and Primary Biliary Cholangitis.

Yao M, Wang L, Wang J, Liu Y, Liu S, Zhao J Dis Markers. 2022; 2022:4253566.

PMID: 35075376 PMC: 8783716. DOI: 10.1155/2022/4253566.

Golgi Phosphoprotein 73: The Driver of Epithelial-Mesenchymal Transition in Cancer.

Liu Y, Hu X, Liu S, Zhou S, Chen Z, Jin H Front Oncol. 2021; 11:783860.

PMID: 34950590 PMC: 8688837. DOI: 10.3389/fonc.2021.783860.

References

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

OShea R, Dasarathy S, McCullough A . Alcoholic liver disease. Hepatology. 2009; 51(1):307-28. DOI: 10.1002/hep.23258. View

Lok A, McMahon B . Chronic hepatitis B. Hepatology. 2007; 45(2):507-39. DOI: 10.1002/hep.21513. View

Wang M, Long R, Comunale M, Junaidi O, Marrero J, Di Bisceglie A . Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2009; 18(6):1914-21. PMC: 4413450. DOI: 10.1158/1055-9965.EPI-08-0980. View

Mao Y, Yang H, Xu H, Lu X, Sang X, Du S . Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. 2010; 59(12):1687-93. DOI: 10.1136/gut.2010.214916. View

Kladney R, Cui X, Bulla G, Brunt E, Fimmel C . Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology. 2002; 35(6):1431-40. DOI: 10.1053/jhep.2002.32525. View

Manns M, Czaja A, Gorham J, Krawitt E, Mieli-Vergani G, Vergani D . Diagnosis and management of autoimmune hepatitis. Hepatology. 2010; 51(6):2193-213. DOI: 10.1002/hep.23584. View

Lee H, Kim J, Cheong J, Han E, An S, Song J . Prediction of compensated liver cirrhosis by ultrasonography and routine blood tests in patients with chronic viral hepatitis. Korean J Hepatol. 2011; 16(4):369-75. PMC: 3304612. DOI: 10.3350/kjhep.2010.16.4.369. View

Tian L, Wang Y, Xu D, Gui J, Jia X, Tong H . Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int J Cancer. 2010; 129(8):1923-31. DOI: 10.1002/ijc.25838. View

10.

Hu J, Wu D, Liang S, Miao X . GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol. 2009; 27(2):339-45. DOI: 10.1007/s12032-009-9215-y. View

11.

Ganem D, Prince A . Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004; 350(11):1118-29. DOI: 10.1056/NEJMra031087. View

12.

Marrero J, Romano P, Nikolaeva O, Steel L, Mehta A, Fimmel C . GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005; 43(6):1007-12. DOI: 10.1016/j.jhep.2005.05.028. View

13.

Thein H, Yi Q, Dore G, Krahn M . Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008; 48(2):418-31. DOI: 10.1002/hep.22375. View

14.

Yao M, Zhao J, Lu F . Alpha-fetoprotein still is a valuable diagnostic and prognosis predicting biomarker in hepatitis B virus infection-related hepatocellular carcinoma. Oncotarget. 2016; 7(4):3702-8. PMC: 4826163. DOI: 10.18632/oncotarget.6913. View

15.

Terrault N, Bzowej N, Chang K, Hwang J, Jonas M, Murad M . AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2015; 63(1):261-83. PMC: 5987259. DOI: 10.1002/hep.28156. View

16.

Munro S . Localization of proteins to the Golgi apparatus. Trends Cell Biol. 1998; 8(1):11-5. PMC: 7172754. DOI: 10.1016/s0962-8924(97)01197-5. View

17.

Lindor K, Gershwin M, Poupon R, Kaplan M, Bergasa N, Heathcote E . Primary biliary cirrhosis. Hepatology. 2009; 50(1):291-308. DOI: 10.1002/hep.22906. View

18.

Yang J, Roberts L . Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 2010; 7(8):448-58. PMC: 3926946. DOI: 10.1038/nrgastro.2010.100. View

19.

Lok A, Seeff L, Morgan T, Di Bisceglie A, Sterling R, Curto T . Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2008; 136(1):138-48. PMC: 3749922. DOI: 10.1053/j.gastro.2008.09.014. View

20.

. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015; 62(3):932-54. DOI: 10.1002/hep.27950. View